News New Targeted Therapy Safe and Effective in Refractory Non-Hodgkin’s Lymphoma Patients Treatment with a new targeted therapy, duvelisib, has shown sustained efficacy and safety in a…adminJuly 7, 2017
News Manitoba Leads the Way in CLL Research and Treatment Recently, a group of Manitoba CLL experts formed the Integrated Multidisciplinary CLL Research Cluster –…adminJuly 7, 2017
News Hodgkin Lymphoma Patient, Survivor & Caregiver Surveys If you have or had Hodgkin lymphoma or you are or were a caregiver of…adminJune 5, 2017
EventsNews Living Well with CLL in Montreal Living Well with CLL in Montreal Chronic Lymphocytic Leukemia Connection Group Seeking to meet the…adminJune 5, 2017
News CLL & SLL Patient & Caregiver Surveys If you have chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) or you…adminMay 25, 2017
News CAR-T Cell Therapy Shows Promise in Aggressive NHL Promising results from the phase 1 portion of a multi-center phase 1/2 clinical trial (ZUMA-1…adminApril 4, 2017
News Pembrolizumab may help those with relapsed NK-cell and T-cell lymphomas A small study suggests that pembrolizumab may provide lasting remissions in some patients with NK-cell…adminApril 4, 2017
NewsResearch Health Canada Approves GAZYVA® for Patients with Previously Treated Follicular Lymphoma New targeted treatment now available for Canadians living with the most common form of slow-growing, non-Hodgkin's…adminFebruary 13, 2017
News BCCA Provincial Systemic Therapy Program approves new program The BCCA Provincial Systemic Therapy Program approves Bendamustine With Rituximab for Previously Untreated CLL or…adminJanuary 13, 2017
NewsResearch pCODR Final Recommendation Issued for idelalisib (Zydelig) for Follicular Lymphoma On September 29, 2016, the pCODR Expert Review Committee (pERC) issued a final recommendation for…adminDecember 16, 2016